IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Quest Laboratories IPO is a Book Building listing on NSE EMERGE exchange. The company is based in Dhar and caters to Pharmaceutical sector. Shreni Shares is the merchant banker of Quest Laboratories IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 1st March 2024.
Quest Laboratories IPO posted revenues of ₹ 82.89 crores and PAT of ₹ 10.32 crores in FY24 on annualised basis.
Revenue:
₹ 82.77 Cr.
EBITDA Margin:
19.47
% 
Net Worth: ₹ 22.77 Cr.
Market Capitalisation:
₹ 158.96 Cr.
P/E:
15.38 times
P/BV: 2.41 times
EV/EBITDA: 10.14 times
Financial results of Quest Laboratories IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Dec-23 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 58.69 | 46.65 | 34.80 | 18.40 | |
| Net Worth | 22.77 | 15.02 | 9.99 | 5.89 | |
| Total Debt | 4.61 | 4.10 | 3.13 | 3.04 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
62.08
82.77 |
61.64 | 59.48 | 30.36 | |
EBITDA
EBITDA on annualised basis |
12.09
16.12 |
7.82 | 6.47 | 1.42 | |
PAT
PAT on annualised basis |
7.75
10.33 |
5.03 | 4.11 | 0.66 | |
Quest Laboratories IPO PAT Margin is 12.48 % , ROCE (Return on Capital Employed) is 41.86 % as per latest financial. The below table shows Quest Laboratories IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Dec-23 | FY23 | FY22 | FY21 |
|---|---|---|---|---|
| EBITDA Margin (%) | 19.47 | 12.69 | 10.88 | 4.68 |
| PAT Margin (%) | 12.48 | 8.16 | 6.91 | 2.17 |
| EPS (₹) | 7.18 | 4.66 | 3.81 | 0.61 |
| ROE (%) | 34.04 | 33.49 | 41.14 | 11.21 |
| ROCE (%) | 41.86 | 38.03 | 44.65 | 11.82 |
| ROA (%) | 13.20 | 10.78 | 11.81 | 3.59 |
| Debt to Equity | 0.20 | 0.27 | 0.31 | 0.52 |
The market Capitalisation of Quest Laboratories IPO is ₹ 158.96 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Quest Laboratories IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Quest Laboratories IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Quest Laboratories IPO is ₹ 158.96 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Quest Laboratories IPO has a Price-to-Earnings (PE) ratio of 15.38 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Quest Laboratories IPO reported revenue of ₹ 82.89 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Quest Laboratories IPO provide insights into sales growth, market demand, and business scalability.
Quest Laboratories recorded an EBITDA of ₹ 16.12 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Quest Laboratories Profit After Tax (PAT) is ₹ 10.33 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 82.77 Cr.
EBITDA Margin:
19.47
%
Net Worth: ₹ 22.77 Cr.
Market Capitalisation:
₹ 158.96 Cr.
P/E:
15.38 times
P/BV: 2.41 times
EV/EBITDA: 10.14 times
Quest Laboratories operates in Pharmaceutical and Pharmaceutical Company Manufacturing A Range Of Antibiotics. The Issue is listed on NSE EMERGE in May, 2024. Quest Laboratories IPO size was 43.16 with Issue price of 97.00 .
Merchant Banker(s) of Quest Laboratories IPO: Shreni Shares Limited
Quest Laboratories IPO subscription was 85.26 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Quest Laboratories IPO listed at a listing price of 147.35 against the offer price of 97.00.
The current market price of Quest Laboratories is 109.80.
Why Us?
